Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)
Avalo Therapeutics (AVTX) posted Gross Margin of 186.75% for Q3 2024, down 234.64% on a QoQ basis from 138.7% in Q4 2023, and down 18209.0% year-over-year from N/an in Q4 2023.
Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024) Analysis & Trends
Avalo Therapeutics' Gross Margin history runs 8 years deep, the most recent figure standing at 186.75% for Q3 2024.
- Quarterly Gross Margin fell 18209.0% year-over-year to 186.75% in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 11.71% (down 1722.0% YoY) and the FY2023 annual result came in at 33.26%, down 4771.0% from the prior year.
- Gross Margin was 186.75% for Q3 2024 at Avalo Therapeutics, down from 138.7% in the prior quarter.
- Across five years, Gross Margin topped out at 138.7% in Q4 2023 and bottomed at 186.75% in Q3 2024.
- A 5-year average of 31.49% and a median of 38.62% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2021 — Gross Margin sank 18833 bps — and 2022, when it soared 12441 bps.
- Avalo Therapeutics' Gross Margin stood at 94.72% in 2020, then plunged by 199 bps to 93.61% in 2021, then soared by 133 bps to 30.8% in 2022, then surged by 350 bps to 138.7% in 2023, then slumped by 235 bps to 186.75% in 2024.
- Business Quant data shows AVTX's Gross Margin at 186.75% in Q3 2024, 138.7% in Q4 2023, and 4.66% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -186.75% |
| Dec 31, 2023 | 138.70% |
| Sep 30, 2023 | -4.66% |
| Jun 30, 2023 | -10.11% |
| Mar 31, 2023 | -16.00% |
| Dec 31, 2022 | 30.80% |
| Sep 30, 2022 | 96.47% |
| Jun 30, 2022 | -51.69% |
| Mar 31, 2022 | 38.62% |
| Dec 31, 2021 | -93.61% |
| Sep 30, 2021 | 32.74% |
| Jun 30, 2021 | 97.53% |
| Mar 31, 2021 | 83.72% |
| Dec 31, 2020 | 94.72% |
| Sep 30, 2020 | 93.07% |
| Jun 30, 2020 | 94.17% |
| Mar 31, 2020 | 97.60% |
| Dec 31, 2019 | 73.80% |
| Sep 30, 2019 | 93.99% |
| Jun 30, 2019 | -6.91% |